Epidermal growth factor receptor (EGFR) and its downstream pathways (such as Ras-MAPK/PI3K-AKT-mTOR) are involved in the tumorigenesis of many cancers, especially in KRAS oncogene mutant-driven cancers such as PDAC (at least 90% of PDAC patients harbor KRAS oncogene mutations and there are few effective strategies) [9, 10]. This evidence concerns the gene EGFR and cancer.